HSNOHbio is an emerging biotechnology venture based in New York, USA, focused on AI-driven discovery and development of next-generation therapeutics for central nervous system (CNS) disorders.
Our lead research program, G3-01EG, is a computationally designed small-molecule candidate being developed to investigate selective allosteric modulation of the GluA3 AMPA receptor.
By integrating artificial intelligence, structure-based molecular design, and experimental validation strategies, HSNOHbio aims to advance precision approaches to neurological and psychiatric disorders.
To transform innovative molecular discoveries into next-generation CNS therapeutics with the potential to improve human health worldwide.
Accelerating CNS drug discovery through AI-assisted molecular engineering, receptor subtype selectivity, and strategic scientific collaboration.